Hemp Industry Daily reports
A panel of government health advisers gave a unanimous recommendation Thursday to the U.S. Food and Drug Administration to approve Epidiolex, a CBD medicine for rare epilepsy conditions that don’t respond to other drugs.
A final decision on rescheduling would be made by the U.S. Drug Enforcement Administration and the FDA’s parent agency, the U.S. Department of Health and Human Services.
The advisory panel’s 13-0 recommendation doesn’t bind the agency to approving Epidiolex, but its recommendations carry serious weight.
The FDA has said it will issue a decision by late June.
The Marijuana Times report
A quick Google share price search shows what the decision means for the company and shareholders
1:35Pm Friday 20 April ( Sydney Australia Time)
Meanwhile in Colorado the battle lines are already being drawn.
Earlier in the week House Bill 18-1187 was presented and entitled
“CONCERNING THE LAWFUL USE OF A PRESCRIPTION DRUG THAT”CONTAINS CANNABIDIOL THAT IS APPROVED BY THE UNITED” “STATES FOOD AND DRUG ADMINISTRATION.”
See our piece ….
Amendments to HB 18-1187 are on the way and we will publish when they are public.
We have a feeling this one will run for a while and not just in Colorado.